Evidence map›Paper›PMID 42236623›Full record

ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2026

ACY-1215 ameliorates experimental colitis by inhibiting dendritic cell maturation and Th1/Th17 responses.

Libin Chen, Yuqing Wen, Shuyu Ye, Xintong Jin, Wenhao Wang, Yanwei Luo, Yifu Xu, Daosheng He, Xiangren Chen, Jian Ma and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Libin Chen *Department of Gastroenterology, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
Yuqing Wen *Hunan Key Laboratory of Nonresolving Inflammation and Cancer, Central South University, Changsha, Hunan, China.
Shuyu YeDepartment of Gastroenterology, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
Xintong JinDepartment of Gastroenterology, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
Wenhao WangDepartment of Thyroid and Breast Surgery, the First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, China.
Yanwei LuoDepartment of Blood transfusion, The third Xiangya Hospital, Central South University, Hunan, China.
Yifu XuXiangya School of Medicine, Central South University, Changsha, China.
Daosheng HeGuiGang City People's Hospital, Guigang, Guangxi, China.
Xiangren ChenGuiGang City People's Hospital, Guigang, Guangxi, China.
Jian MaHunan Key Laboratory of Nonresolving Inflammation and Cancer, Central South University, Changsha, Hunan, China.
Xiayu LiDepartment of Gastroenterology, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China. lixiayu@csu.edu.cn.
Feiyan AiDepartment of Gastroenterology, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China. aifeiyan1105@csu.edu.cn.

Funding

College Students'Innovative Entrepreneurial Training Plan Program S202510533293Hunan Provincial Innovation Foundation For Postgraduate CX20240025the Fundamental Research Funds for the Central Universities of Central South University No. 2026ZZTS0134the National Natural Science Foundation of China 82172766the Project of Hunan Provincial Health Commission No.20231824
6 · The paper itself

Abstract

objectiveTo evaluate the therapeutic potential of ACY-1215, a selective histone deacetylase 6 inhibitor, in inflammatory bowel disease and to provide mechanistic insights into its effects on dendritic cell-driven T-cell responses.

methodsA dextran sulfate sodium-induced murine colitis model was used to assess the effects of ACY-1215 on disease severity, colon injury, epithelial barrier integrity, and tight junction protein expression. Bulk transcriptomic profiling of colonic tissues was performed to identify altered immune pathways. A public single-cell RNA-seq dataset, GSE134809, was reanalyzed to obtain cell-type-resolved evidence. Functional assays were conducted to examine the effects of ACY-1215 on dendritic cell maturation, migration, and dendritic cell-mediated Th1/Th17 polarization.

resultsACY-1215 markedly alleviated DSS-induced colitis, as shown by reduced body weight loss, ameliorated colon shortening, attenuated histopathological injury, and restoration of tight junction protein expression. Bulk transcriptomic analysis indicated suppression of antigen-presentation programs, including reduced MHC-II-related signatures, following ACY-1215 treatment. Single-cell RNA-seq analysis implicated increased dendritic cell-T cell communication together with elevated Th1/Th17 immune programs in inflamed intestine. Consistently, ACY-1215 inhibited dendritic cell maturation and migration and consequently attenuated Th1 and Th17 polarization.

conclusionsThese findings support selective HDAC6 inhibition as an immunoepigenetic strategy that restrains dendritic cell-driven T-cell responses and promotes mucosal homeostasis, highlighting ACY-1215 as a mechanism-based therapeutic candidate for inflammatory bowel disease.

Indexed as

ColitisDendritic CellsHistone Deacetylase InhibitorsHydroxamic AcidsTh17 CellsTh1 CellsAnimalsColonDextran SulfateMiceMice, Inbred C57BLDextran SulfateHistone Deacetylase InhibitorsHydroxamic AcidsACY-1215Dendritic cellsImmune responseInflammatory bowel diseaseIntestinal barrier

Identifiers

PMID42236623

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.